We are live on ! Find out more
FCMI

Foresite Capital Management II Portfolio holdings

AUM $29.2M
1-Year Est. Return 44.84%
This Fund
S&P 500
This Quarter Est. Return
-25.66%
1 Year Est. Return
+44.84%
3 Year Est. Return
-66.21%
5 Year Est. Return
-36.36%
10 Year Est. Return
–
AUM
$204M
AUM Growth
-$93.9M
Cap. Flow
-$3.11M
Cap. Flow %
-1.52%
Top 10 Hldgs %
87.82%
Holding
24
New
–
Increased
9
Reduced
5
Closed
4

Top Buys

Rank Stock Value
1
AERI
Aerie Pharmaceuticals
AERI
+$3.34M
2
ALDR
Alder Biopharmaceuticals
ALDR
+$2.56M
3
NSTG
NanoString Technologies, Inc.
NSTG
+$2.4M
4
RGLS
Regulus Therapeutics
RGLS
+$1.91M
5
XLRN
Acceleron Pharma
XLRN
+$1.07M

Top Sells

Rank Stock Value
1
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
+$5.4M
2
QTNT
Quotient Limited Ordinary Shares
QTNT
+$3.08M
3
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$1.17M
4
BDSI
BioDelivery Sciences International, Inc.
BDSI
+$755K
5
LRMR icon
Larimar Therapeutics
LRMR
+$435K

Sector Composition

Rank Sector Weight
1 Healthcare 65.78%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AIMT
1
DELISTED
Aimmune Therapeutics
AIMT
$55.4M 27.13%
4,087,900
– –
UAM
2
DELISTED
Universal American Corp
UAM
$20.1M 9.84%
2,814,883
– –
KDNY
3
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$16.9M 8.29%
264,583
-66,816
-20% -$5.4M
EPZM
4
DELISTED
Epizyme, Inc
EPZM
$14.4M 7.07%
1,191,995
+32,200
+3% +$326K
ADAP
5
DELISTED
Adaptimmune Therapeutics
ADAP
$14.3M 7.01%
1,761,567
– –
RGLS
6
DELISTED
Regulus Therapeutics
RGLS
$14.1M 6.92%
16,991
+2,402
+16% +$1.91M
ALDR
7
DELISTED
Alder Biopharmaceuticals
ALDR
$13M 6.36%
530,416
+110,419
+26% +$2.56M
AERI
8
DELISTED
Aerie Pharmaceuticals
AERI
$11.5M 5.65%
949,372
+211,011
+29% +$3.34M
NSTG
9
DELISTED
NanoString Technologies, Inc.
NSTG
$10M 4.91%
659,486
+170,000
+35% +$2.4M
LRMR icon
10
Larimar Therapeutics
LRMR
$416M
$9.5M 4.65%
118,523
-5,511
-4% -$435K
XLRN
11
DELISTED
Acceleron Pharma
XLRN
$4.59M 2.25%
174,089
+36,631
+27% +$1.07M
ARDX icon
12
Ardelyx
ARDX
$1.24B
$3.64M 1.78%
468,297
-10,000
-2% -$98.4K
OREX
13
DELISTED
Orexigen Therapeutics, Inc.
OREX
$3.64M 1.78%
646,208
+23,703
+4% +$308K
NVET
14
DELISTED
Nexvet Biopharma plc Ordinary Shares
NVET
$2.93M 1.43%
887,801
+13,800
+2% +$45K
BDSI
15
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$2.4M 1.18%
743,395
-204,420
-22% -$755K
ANAC
16
PUT
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
$2M 0.98%
31,000
– –
RGNX icon
17
Regenxbio
RGNX
$623M
$1.69M 0.83%
156,741
– –
NDRM
18
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$1.69M 0.83%
119,781
+64,002
+115% +$865K
SCYX icon
19
SCYNEXIS
SCYX
$37M
$1.36M 0.67%
4,215
– –
BDSI
20
PUT
DELISTED
BioDelivery Sciences International, Inc.
BDSI
$943K 0.46%
209,500
-500
-0.2% -$1.85K
SIOX
21
DELISTED
Sio Gene Therapies Inc. Common Stock
SIOX
– –
-8,125
Closed -$1.17M
QTNT
22
DELISTED
Quotient Limited Ordinary Shares
QTNT
– –
-4,804
Closed -$3.08M
BDSI
23
CALL
DELISTED
BioDelivery Sciences International, Inc.
BDSI
– –
-310,000
Closed -$1.49M
ANAC
24
CALL
DELISTED
ANACOR PHARMACEUTICALS INC COM
ANAC
– –
-31,000
Closed -$3.5M

Similar funds

AG
Appleton Group Appleton, Wisconsin $28.6M AUM 32.21% 1-Year Est. Return
SAM
Sandbar Asset Management London, United Kingdom $30.5M AUM 46.07% 1-Year Est. Return
AC
Amia Capital London, United Kingdom $32.1M AUM 0.56% 1-Year Est. Return
QI
Qualcomm Inc San Diego, California $32.1M AUM 5.35% 1-Year Est. Return
TAAM
Top Ace Asset Management Hong Kong $25.3M AUM 23.27% 1-Year Est. Return
NAM
Nationwide Asset Management Columbus, Ohio $25.1M AUM 13.37% 1-Year Est. Return
MSKCC
Memorial Sloan Kettering Cancer Center New York $24.6M AUM 10.16% 1-Year Est. Return
BRC
Bishop Rock Capital New York $24.3M AUM 20.73% 1-Year Est. Return

Foresite Capital Management II's Q1 2016 Portfolio in Review

As of Q1 2016, Foresite Capital Management II held 24 positions worth $204M, down 31% from $298M the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Foresite Capital Management II's Q1 2016 filing shows 9 increased, 5 reduced and 4 closed positions. The largest sale was Chinook Therapeutics, Inc. Common Stock, an estimated $5.4M.

By sector, the portfolio is most concentrated in Healthcare at 66% of assets, up from 65% a quarter earlier.

  • Foresite Capital Management II added most to Aerie Pharmaceuticals in Q1 2016, an estimated $3.34M increase.
  • Foresite Capital Management II's biggest Q1 2016 reduction was Chinook Therapeutics, Inc. Common Stock, cutting an estimated $5.4M.
  • Foresite Capital Management II fully exited Quotient Limited Ordinary Shares in Q1 2016, selling an estimated $3.08M.
  • Foresite Capital Management II's ten largest holdings make up 88% of its $204M portfolio in Q1 2016.
  • Foresite Capital Management II opened 0 new positions and closed 4 in Q1 2016.
  • Foresite Capital Management II's portfolio value fell 31% quarter-over-quarter to $204M.

Based on Foresite Capital Management II's 13F filing for Q1 2016, filed 6 May 2016.